Monoclonal antibody approved for the treatment of moderate-to-severe Crohn's disease

被引：0
|
作者：
不详
机构：
来源：
FORMULARY | 2008年 / 43卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：40 / +
页数：2
相关论文
共 50 条
  • [1] Upadacitinib for the treatment of moderate-to-severe Crohn's disease
    Hanzel, Jurij
    Ma, Christopher
    Jairath, Vipul
    [J]. IMMUNOTHERAPY, 2024, 16 (06) : 345 - 357
  • [2] A new treatment for moderate-to-severe Crohn's disease
    Aschenbrenner, Diane S.
    [J]. AMERICAN JOURNAL OF NURSING, 2008, 108 (05) : 65 - 65
  • [3] Evaluating the pharmacokinetics of upadacitinib for the treatment of moderate-to-severe Crohn's disease
    Faggiani, Ilaria
    D'Amico, Ferdinando
    Bernardi, Francesca
    Bencardino, Sarah
    Allocca, Mariangela
    Furfaro, Federica
    Parigi, Tommaso Lorenzo
    Zilli, Alessandra
    Fiorino, Gionata
    Peyrin-Biroulet, Laurent
    Danese, Silvio
    [J]. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2024, 20 (05) : 297 - 305
  • [4] Cimzia - Certolizumab pegol - UCB - Tumor necrosis factor blocker approved for the treatment of moderate-to-severe Crohn's disease
    不详
    [J]. FORMULARY, 2008, 43 (06) : 188 - 188
  • [5] A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease
    Sandborn, William J.
    Feagan, Brian G.
    Fedorak, Richard N.
    Scherl, Ellen
    Fleisher, Mark R.
    Katz, Seymour
    Johanns, Jewel
    Blank, Marion
    Rutgeerts, Paul
    [J]. GASTROENTEROLOGY, 2008, 135 (04) : 1130 - 1141
  • [6] Humira® (Adalimumab) Approved in Europe for the treatment of Moderate-Severe Crohn's disease
    Nienstedt, Maren
    [J]. VISZERALMEDIZIN, 2012, 28 (05): : 356 - 356
  • [7] Efalizurnab, a humanized anti-cd11a monoclonal antibody, in the treatment of moderate to severe Crohn's disease
    James, Dustin G.
    Holinga, Julie A.
    Seo, Da hea
    Stone, Christian D.
    [J]. GASTROENTEROLOGY, 2007, 132 (04) : A506 - A506
  • [8] Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease
    Peyrin-Biroulet, Laurent
    Chapman, J. Casey
    Colombel, Jean-Frederic
    Caprioli, Flavio
    D'Haens, Geert
    Ferrante, Marc
    Schreiber, Stefan
    Atreya, Raja
    Danese, Silvio
    Lindsay, James O.
    Bossuyt, Peter
    Siegmund, Britta
    Irving, Peter M.
    Panaccione, Remo
    Cao, Qian
    Neimark, Ezequiel
    Wallace, Kori
    Anschutz, Toni
    Kligys, Kristina
    Duan, W. Rachel
    Pivorunas, Valerie
    Huang, Xiu
    Berg, Sofie
    Shu, Lei
    Dubinsky, Marla
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2024, 391 (03): : 213 - 223
  • [9] Efficacy of Adalimumab in Moderate-to-Severe Pediatric Crohn's Disease
    Viola, Franca
    Civitelli, Fortunata
    Di Nardo, Giovanni
    Barbato, Maria Beatrice
    Borrelli, Osvaldo
    Oliva, Salvatore
    Conte, Francesca
    Cucchiara, Salvatore
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2009, 104 (10): : 2566 - 2571
  • [10] Variables associated with progression of moderate-to-severe Crohn's disease
    Beda Sacramento, Carolina da Silva
    Motta, Marina Pamponet
    Alves, Candida de Oliveira
    Mota, Jaciane Araujo
    Codes, Lina Maria Goes de
    Ferreira, Reginaldo Freitas
    Silva, Pedro de Almeida
    Palmiro, Larissa do Prado
    Barbosa, Rafael Miranda
    Andrade, Mariana Nery
    Andrade, Vitor Damasceno
    Vasconcelos, Vitor Brandao
    Thiara, Bernardo Wasconcellos
    Netto, Eduardo Martins
    Santana, Genoile Oliveira
    [J]. BMJ OPEN GASTROENTEROLOGY, 2022, 9 (01):
12345